Ildong gets exclusive right for paclitaxel PM technology

Published: 2007-11-15 06:56:00

Updated: 2007-11-15 06:56:00

Ildong Pharm has recently obtained an exclusive license for developing paclitaxel PM product and its delivery system in a strategic partnership with a Chinese company that received a Chinese patent in January of this year.

Paclitaxel PM is an innovative new formulation of the widely used anti-...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK